China's CanSino new crown vaccine receives WHO emergency use certification
China News Agency, May 22 (Reporter Zhang Penghui) The World Health Organization recently announced that the recombinant new crown vaccine Kwesa, developed by China CanSino Biological Co., Ltd., has officially passed the WHO emergency use certification.
This is the third Chinese new crown vaccine certified by WHO for emergency use after Sinopharm and Kexing vaccine.
The WHO said in a statement that according to the WHO emergency use certification process, the quality, safety, efficacy, risk management planning, program applicability and on-site production of CanSino’s new crown vaccine have been evaluated.
"The Emergency Use List Technical Advisory Group convened by WHO and comprised of regulatory experts from around the world determined that the vaccine meets WHO's standards for protection against 2019-nCoV and that the benefits of the vaccine far outweigh the risks."
The WHO said the vaccine was 64 percent effective at preventing symptomatic infection with the new coronavirus and 92 percent effective at preventing severe disease.
The CanSino vaccine was previously reviewed by the WHO Strategic Advisory Group of Experts on Immunization, which recommended the use of a single 0.5ml dose of CanSino in all age groups 18 years and older.